BioSpace News Archive

Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous product,as reported by Johnson & Johnson were USD 2,052 million in the third quarter of 2022.

NuGen Medical Devices Inc., a leader in needle-free drug delivery, is pleased to announce that it has received confirmation of its official certification for its wholly owned subsidiary European Pharma Group B.V.

ViewRay, Inc. announced the launch of a phase III randomized controlled trial titled “Locally Advanced Pancreatic cancer treated with ABLAtivE stereotactic MRI-guided adaptive radiation therapy” – also known as LAP-ABLATE.

Zomedica Corp. announced that Larry Heaton, Zomedica’s Chief Executive Officer, is scheduled to provide a company overview and its prospects for growth at the LD Micro Main Event XV Conference on October 25, 2022 at the Luxe Sunset Boulevard Hotelin Bel Air, California.

Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.

Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion, recommending that the orphan disease designation of Mycapssa® in the treatment of acromegaly in the European Union (EU) is maintained.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the LD Micro Main Event XV.

Aligos Therapeutics, Inc. today announced that the Company will make an oral presentation at the Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference being held October 17-20, 2022 in Boston, MA.

AnPac Bio-Medical Science Co., Ltd. today announced that it plans to change the ratio of the Company’s American Depositary Shares (“ADSs”) to its Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing twenty (20) Class A ordinary shares.

Alphyn Biologics announced today that enrollment in its Phase2a clinical trial of AB-101a for mild-to-moderate atopic dermatitis (AD) has passed the halfway point.